Published March 15, 2024 | Version v1
Journal article Open

V International expert forum on menopausal hormone therapy

Authors/Creators

  • 1. Samarkand Medical Institute, Samarkand, Uzbekistan
  • 2. Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, Kazakhstan
  • 3. SSI "Center for Innovative Medical Technologies of the NAS of Ukraine"; Polyclinic No. 2 of the State Scientific Institution "Center of Innovative Medical Technologies of the NAS of Ukraine", Kyiv, Ukraine
  • 4. Tashkent Institute of Advanced Medical Education, Tashkent, Uzbekistan
  • 5. Zurab Sabakhtarashvili Reproductive Clinic, Tbilisi, Georgia
  • 6. Institute of Reproductive Medicine; Kazakhstan Association of Sexual and Reproductive Health, Almaty, Kazakhstan
  • 7. Bogomolets National Medical University, Kyiv, Ukraine
  • 8. Institute of Reproductive Medicine, Almaty, Kazakhstan
  • 9. Odesa National Medical University, Odesa, Ukraine
  • 10. SI "O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine", Kyiv, Ukraine
  • 11. Karaganda Medical University; Karaganda branch of the KMPA, Karaganda, Kazakhstan
  • 12. SSI "Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv, Ukraine
  • 13. Ivane Javakhishvili Tbilisi State University; Center for Reproductive Medicine "University", Tbilisi, Georgia
  • 14. SI "National Scientific Center "M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine" of the NAMS of Ukraine, Kyiv, Ukraine
  • 15. Center of Molecular Medicine, Almaty, Kazakhstan
  • 16. P.L. Shupyk National University of Health Care of Ukraine, Kyiv, Ukraine
  • 17. Medical Center "Asthik", Yerevan, Armenia
  • 18. Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
  • 19. SSI "Center for Innovative Medical Technologies of the NAS of Ukraine", Kyiv, Ukraine
  • 20. Family Planning Center, Baku, Azerbaijan
  • 21. Medical Center "Baku", Baku, Azerbaijan
  • 22. Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of
  • 23. SI "O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine"; SSI "Center for Innovative Medical Technologies of the NAS of Ukraine", Kyiv, Ukraine
  • 24. SI "O.M. Lukyanova IPOG of the NAMS of Ukraine"; SSI "Center for Innovative Medical Technologies of the NAS of Ukraine", Kyiv, Ukraine
  • 25. National Scientific Center of Motherhood and Childhood of the CF "University Medical Center", Astana, Kazakhstan
  • 26. Medicom Clinic, Kyiv, Ukraine

Description

On November 23, 2023, the V International Forum of Experts on Menopausal Hormone Therapy (MHT) was held. The Expert Council’s working group included leading experts in the field of endocrine gynaecology and related areas from Azerbaijan, Armenia, Georgia, Kazakhstan, Moldova, Uzbekistan, and Ukraine.
The Forum experts noted the importance of dialogue and understanding between doctor and patient, the need for interdisciplinary integration between doctors of those specialties that deal with women’s health issues. Close cooperation with related specialists who provide care to women is necessary, as they are often the ones who encounter the first manifestations of menopause in patients and can therefore refer them to an obstetrician-gynaecologist in a timely manner.
The experts reviewed the issue of cardiovascular risk and MHT and determined the following benefit/risk ratio for the cardiovascular effects of MHT:
• MHT is not recommended for women at high cardiovascular risk or with previous cardiovascular disease;
• MHT may reduce the risk of CVD-related all-cause death in women < 60 years of age and with menopause of up to 10 years;
• timely initiation of MHT (in women under 60 years of age or within 10 years of menopause) has the greatest cardiovascular health benefits.
The forum updated the Algorithm for prescribing MHT in premature and early menopause and addressed the management of women with polycystic ovary syndrome
in menopause. Since the majority of women with this syndrome are overweight and obese, they should use the most metabolically neutral drugs, i.e. those containing didrogesterone or progesterone, for MHT. MHT with didrogesterone has a favourable safety profile in relation to the most common risks of MHT: does not increase the risk of breast cancer and venous thromboembolism, has a favourable safety profile with respect to the endometrium, and does not affect metabolism.

Notes

https://reproduct-endo.com/article/view/301891

Files

V International expert forum on menopausal hormone therapy.pdf

Files (788.8 kB)

Additional details

References

  • Order of the MOH of Ukraine dated June 17, 2022 "On approval of the Unified clinical protocol of the primary, secondary (specialized), tertiary (highly specialized) medical assistance «Menopausal disorders and other disorders in perimenopausal period»" [Internet]. Kyiv: State Expert Center of the Ministry of Health of Ukraine, 2022. Available from: https://www.dec.gov.ua/mtd/menopauzalni-porushennya-ta-inshi-rozlady-v-perymenopauzalnomu-periodi/
  • Maas AHEM, Rosano G, Cifkova R, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J. 2021 Mar 7;42(10):967–84. DOI: 10.1093/eurheartj/ehaa1044.
  • Stevenson JC, Rioux JE, Komer L, Gelfand M. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Climacteric. 2005;8:352–9. DOI: 10.1080/13697130500345190.
  • Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–337. DOI: 10.1093/eurheartj/ehab484.
  • Fleg JL, Stone GW, Faya ZA, et al. Detection of High-Risk Atherosclerotic Plaque:Report of the NHLBI Working Group on Current Status and Future Directions. JACC Cardiovasc Imaging. 2012 September; 5(9):941–55. DOI: 10.1016/j.jcmg.2012.07.007.
  • Giri R, Vincent AJ. Prevalence and Risk Factors of Premature Ovarian Insufficiency/Early Menopause. Semin Reprod Med. 2020;38(4–05):237–246. DOI:10.1055/s-0040-1722317
  • Golezar S, Ramezani Tehrani F, Khazaei S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric 2019;22:403–11. DOI: 10.1080/13697137.2019.1574738.
  • Goswami D, Conway GS. Premature ovarian failure. Hum Rep Update 2005; 11 (4):391-410. DOI: 10.1093/humupd/dmi012.
  • Baber R.J. Panay N, Fenton A; IMS Writing Group. IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016; 19:109–50. DOI: 10.3109/13697137.2015.1129166
  • Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020 Oct;23(5):426–446. DOI: 10.1080/13697137.2020.1804547.
  • Lambrinoudaki I, Paschou SA, Lumsden MA, et al. Premature ovarian insufficiency: A toolkit for the primary care physician. Maturitas. 2021;147:53-63. DOI:10.1016/j.maturitas.2020.11.004
  • Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19(1): 41–7. DOI: 10.1093/humrep/deh098
  • Helvaci N, Yildiz BO. Polycystic ovary syndrome and aging: Health implications after menopause. Maturitas. 2020 Sep:139:12–9. DOI: 10.1016/j.maturitas.2020.05.013
  • Minooee S, Tehrani FR, Rahmati M, et al. Prediction of age at menopause in women with polycystic ovary syndrome. Climacteric. 2018;21(1):29–34. DOI:10.1080/13697137.2017.1392501
  • Millán-de-Meer M, Luque-Ramírez M, Nattero-Chávez L, Escobar-Morreale HF. PCOS during the menopausal transition and after menopause: a systematic review and metaanalysis. Human Reprod Update. 2023 Nov 2;29(6):741-772. DOI: 10.1093/humupd/dmad015
  • Teede HJ, Tay CT, Laven J, et al; International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023 Sep 5;38(9):1655–79. DOI: 10.1093/humrep/dead156.
  • Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447–69. DOI: 10.1210/clinem/dgad463.
  • Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113:65–73. DOI: 10.1097/AOG.0b013e31818e8cd6.
  • Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA. 2020 Jul 28;324(4):369–80. DOI: 10.1001/jama.2020.9482.
  • Franke НR, Vermes I. Differential effects of progestogens оn breast cancer cell lines. Maturitas. 2003; 46 Suppl 1:S55-S58. DOI: 10.1016/j. maturitas.2003.09.019
  • Fournier А, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107(1):103-11. DOI: 10.1007/s10549-007-9523-x.
  • Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020;371:m3873. DOI: 10.1136/bmj.m3873.
  • Ferenczy A, Gelfand MM, van de Weijer PHM, Rioux JE. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17b-estradiol combined with sequential 5–20mg dydrogesterone. Climacteric. 2002;5:26–35
  • Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. DOI: 10.1136/bmj.k4810.
  • Anagnostis P, Bitzer J, Cano A, et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135:82–8. DOI: 10.1016/j.maturitas.2020.03.007.
  • Pourhadi N, Mоrch LS, Holm EA et al. Menopausal hormone therapy and dementia: nationwide, nested case-control study. BMJ2023;381:e072770. DOI: 10.1136/bmj-2022-072770.
  • Rapp SR, Espeland MA, Shumaker SA et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003. May 28;289(20):2663–72. DOI: 10.1001/jama.289.20.2663
  • Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016;374(13):1221–31. DOI:10.1056/NEJMoa1505241
  • Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26(9):1071–84. DOI:10.1097/GME.0000000000001326
  • Vinogradova Y, Dening T, Hippisley-Cox J, et al. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ 2021; 375:n2182. DOI: 10.1136/bmj.n2182.
  • Kim Y J, Soto M, Branigan G L, et al. Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. Alzheimers Dement (N Y). 2021 May 13;7(1):e12174. DOI: 10.1002/trc2.12174.